Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
EPAS1 was detected in all of the RCC cell lines examined.
|
11301389 |
2001 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
HIF-2α is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation.
|
22869144 |
2013 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma.
|
26439684 |
2015 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
HIF2A germline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma.
|
29172931 |
2017 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23.
|
22010048 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A small molecule inhibitor that binds to HIF-2α and blocks dimerization with HIF-1β is in clinical trials for the treatment of renal cell carcinoma.
|
30625281 |
2019 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) signaling may promote renal cell carcinoma (RCC) progression via altered HIF-2α/VEGF signaling.
|
27848972 |
2016 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cell culture metabolomics analysis was utilized to determined effect of VHL and HIF-1α or HIF-2α on metabolism of renal cell carcinomas (RCC).
|
26620126 |
2016 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer.
|
25826619 |
2015 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
|
15217953 |
2004 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we demonstrate that peroxisome abundance is reduced in VHL-deficient human clear cell renal cell carcinomas with high HIF-2α levels.
|
25440060 |
2014 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies multiple risk loci for renal cell carcinoma.
|
28598434 |
2017 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Herein, we provide mechanistic evidence that HIF-2α can be degraded in cytoplasm under hypoxic conditions via the 26S proteasome and that MDM2 is the E3 ligase which induces the hypoxic degradation of HIF-2α in PI-3K-dependent manner in VHL-deficient RCC cells.
|
25578041 |
2015 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
|
15592504 |
2005 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In determining the critical functions for HIF2α expression in RCC cells, the NADPH oxidase NOX4 has been identified, but the pathogenic contributions of NOX4 to RCC have not been evaluated directly.
|
24755467 |
2014 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In follow-up of a recent genome-wide association study (GWAS) that identified a locus in chromosome 2p21 associated with risk for renal cell carcinoma (RCC), we conducted a fine mapping analysis of a 120 kb region that includes EPAS1.
|
22113997 |
2012 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Knockdowns of TRAIL averted apoptotic cell death caused by HIF2-alpha inhibition in starvation-resistant RCCs.
|
29796174 |
2018 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
|
20032376 |
2009 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
New treatment modalities targeted to HIF-1α and HIF-2α might be planned as well as VEGF-targeted therapies in the management of clear cell renal cell carcinomas.
|
27583351 |
2017 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma.
|
16230378 |
2005 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data provide insight into the link between HIF2α, the ITPR1-related pathway, and natural immunity and strongly suggest a role for the HIF2α/ITPR1 axis in regulating RCC cell survival.
|
25297632 |
2014 |
Renal Cell Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings also suggest that MTHFD2 and HIF-2α form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth.
|
31289360 |
2019 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study confirmed sex-specific associations for two known RCC risk loci at 14q24.2 (DPF3) and 2p21(EPAS1).
|
31231134 |
2019 |
Renal Cell Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
|
28951458 |
2017 |
Renal Cell Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.
|
23940778 |
2013 |